Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Pfizer Stock: Morgan Stanley Raises Target Amid Strong Earnings

Felix Baarz by Felix Baarz
August 6, 2025
in Stocks
0
Pfizer Stock
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

Pfizer’s stock received a boost as Morgan Stanley raised its price target from $32 to $33, reflecting optimism after the pharmaceutical giant reported better-than-expected Q2 results. Adjusted earnings surged 20% year-over-year to $9.6 billion, while revenue grew modestly to $28.4 billion. The company outperformed analyst estimates with Q2 earnings of $0.78 per share, 37% above projections, and revenue of $14.7 billion versus $13.47 billion expected. Management also raised its full-year adjusted EPS guidance to $2.90–$3.10, citing cost-cutting measures and strong performance from drugs like Eliquis and Xeljanz.

Regulatory Risks Loom Despite Growth

While Pfizer’s fundamentals remain strong, regulatory challenges cast a shadow. Potential U.S. tariffs of up to 250% on drug imports and government-mandated price cuts threaten profitability. The company has factored these risks into its 2025 outlook, but investor sentiment remains mixed. Shares rose 5% post-announcement, trading at $24.50, significantly outpacing the S&P 500. Analysts note the stock’s recovery from pandemic lows but caution that regulatory decisions could dictate its future trajectory.

Ad

Pfizer Stock: Buy or Sell?! New Pfizer Analysis from February 7 delivers the answer:

The latest Pfizer figures speak for themselves: Urgent action needed for Pfizer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Pfizer: Buy or sell? Read more here...

Tags: Pfizer
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Uber Stock

Uber Stock: Strong Earnings Met With Market Skepticism

LifeMD Stock

LifeMD Stock: Plunge Amidst Earnings Shock and Growth Concerns

AMD Stock

AMD Stock: Mixed Results Amid China Export Woes

Recommended

Tilray Stock

Tilray Shares Surge Ahead of Quarterly Earnings Report

4 months ago
Science Applications Stock

Institutional Investors Defy Cautious Analyst Stance on Science Applications

5 months ago
Ballard Power Stock

Institutional Investors Bet Big on Ballard Power Shares

2 months ago
Devon Energy Stock

Devon Energy Shares Show Signs of Revival Amid Strong Fundamentals

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Embecta’s Q1 Performance Outpaces Analyst Forecasts

Camping World’s New Leadership Faces First Major Test

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

Diginex Enters Critical Implementation Phase Following Strategic Moves

Deluxe Stock Gains Momentum on Successful Fintech Transition

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Trending

Great Lakes Dredge, Dock Stock
Analysis

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

by Rodolfo Hanigan
February 7, 2026
0

As Great Lakes Dredge & Dock prepares to release its upcoming quarterly figures, investor attention is fixed...

Boston Omaha Stock

Investors Await March Report for Boston Omaha’s Strategic Direction

February 7, 2026
Universal Insurance Stock

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

February 7, 2026
Embecta Stock

Embecta’s Q1 Performance Outpaces Analyst Forecasts

February 7, 2026
Camping World Stock

Camping World’s New Leadership Faces First Major Test

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches
  • Investors Await March Report for Boston Omaha’s Strategic Direction
  • Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com